Filing Flows › Comparisons › RNA vs CVSI
Atrium Therapeutics vs CV Sciences: RNA and CVSI compared
Atrium Therapeutics is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $3.0M for CV Sciences (Q2 2026). CV Sciences is growing faster (-18% against -22% a year earlier). CV Sciences is more profitable, with an operating margin of -10.1% against -752.9%.
Where the money goes: RNA and CVSI
Atrium Therapeutics (RNA) · Q2 2026
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%, net loss $20.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
CV Sciences (CVSI) · Q2 2026
CV Sciences, Q2 2026: revenue $3.0M (-18% year over year), operating margin -10.1%, net loss $775K, operating cash flow $20K. The chart follows the revenue to costs, profit and cash.
| Atrium Therapeutics (RNA) | CV Sciences (CVSI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $3.0M | $3.0M |
| Revenue growth, Y/Y | -22% | -18% |
| Operating margin | -752.9% | -10.1% |
| Net earnings | −$20.2M | −$775K |
| Net margin | -672.0% | -26.0% |
| Operating cash flow | −$3.9M | $20K |
| Free cash flow | — | $13K |
Questions
Which is bigger, Atrium Therapeutics or CV Sciences?
Atrium Therapeutics is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $3.0M for CV Sciences (Q2 2026).
Is Atrium Therapeutics or CV Sciences growing faster?
CV Sciences is growing faster (-18% against -22% a year earlier).
Which is more profitable, Atrium Therapeutics or CV Sciences?
CV Sciences is more profitable, with an operating margin of -10.1% against -752.9%.
More: Atrium Therapeutics earnings · how Atrium Therapeutics makes money · CV Sciences earnings · how CV Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.